CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Drug Reimbursement Recommendation - Trastuzumab Emtansine (Kadcyla) and Cemiplimab (Libtayo)

Published on: January 22, 2020
Result type: News

Today, CADTH has issued final recommendations for:

Trastuzumab Emtansine (Kadcyla) for Early Breast Cancer (EBC)

Funding Request: For the adjuvant treatment of patients with HER2-positive early breast cancer, who have residual disease, after pre-operative systemic treatment. KADCYLA should be continued for 14 cycles or until disease progression or unacceptable toxicity. If KADCYLA is discontinued in the event of toxicity, treatment with trastuzumab may be continued to complete one year of HER2-directed therapy.
Recommendation: Reimburse
Notification to implement target date: February 6, 2020

For more information

Cemiplimab (Libtayo) for Cutaneous Squamous Cell Carcinoma

Funding Request: For the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation.
Recommendation: Reimburse with clinical criteria and/or conditions
Notification to implement target date: February 6, 2020

For more information